Skip to main content

Table 1 Data on hospital-based headache care during the Covid-19 pandemic in Denmark and Norway (N = 29)

From: Hospital-based headache care during the Covid-19 pandemic in Denmark and Norway

  All (N = 29) % (n) Denmark (N = 12) % (n) Norway (N = 17) % (n)
Yes No Yes No Yes No
The situation and duties at work did change 86 (25) 14 (4) 83 (10) 17 (2) 88 (15) 12 (2)
Our work schedule was changed as a consequence of the pandemic 41 (12) 59 (17) 67 (8) 33 (4) 53 (9) 47 (8)
We reduced the number of beds at the neurology department during the pandemic 33 (9) 67 (18) 27 (3) 73 (8) 38 (6) 63 (10)
Fewer patients with acute headache came to the hospital emergency room for assessment than normal 60 (15) 40 (10) 56 (5) 44 (4) 63 (10) 38 (6)
Have you admitted patients with headache as a primary/debut symptom of Covid-19? 24 (7) 76 (22) 33 (4) 67 (8) 18 (3) 82 (14)
Fewer patients with severe migraine/status migrainosus were admitted during the pandemic than normal 68 (17) 32 (8) 56 (5) 44 (4) 75 (12) 25 (4)
Fewer patients with cluster headache attacks were admitted during the pandemic than normal 54 (14) 46 (12) 55 (6) 45 (5) 53 (8) 47 (7)
We reduced activity at the department’s out-patient clinic during the pandemic 83 (24) 17 (5) 83 (10) 17 (2) 82 (14) 18 (3)
We maintained the usual out-patient clinic for headache patients (with in-person appointments as the norm) 17 (5) 83 (24) 8 (1) 92 (11) 24 (4) 77 (13)
We primarily saw patients for follow-ups and not newly referred patients during the pandemic 25 (7) 75 (21) 42 (5) 58 (7) 13 (2) 88 (14)
We switched to primarily telephone consultations for headache patients 86 (25) 14 (4) 83 (10) 17 (2) 88 (15) 12 (2)
We began offering video consultations for headache patients 45 (13) 55 (16) 58 (7) 42 (5) 35 (6) 65 (11)
Did you refrain from using CGRP antibodies during the pandemic? 9 (2) 91 (21) 33 (2) 67 (4) 0 100 (17)
Did you switch more patients from botulinum toxin to CGRP antibodies than normal during the pandemic? 21 (5) 79 (19) 0 100 (7) 29 (5) 71 (12)
Were you more likely to put patients on CGRP antibodies rather than botulinum toxin as a new treatment for chronic migraine during the pandemic? 35 (8) 65 (15) 17 (1) 83 (5) 41 (7) 59 (10)
If you normally use greater occipital nerve injections, did you continue to do so during the pandemic? 60 (12) 40 (8) 71 (5) 29 (2) 54 (7) 46 (6)
Did your Department continue botulinum toxin treatment for chronic migraine during the pandemic? 36 (9) 64 (16) 38 (3) 68 (5) 35 (6) 65 (11)
Did any of your patients have their treatment aids (O2) revoked or postponed? 4 (1) 96 (25) 0 100 (9) 6 (1) 94 (16)
If you were running research projects, were they halted during this period? 57 (13) 43 (10) 50 (4) 50 (4) 60 (9) 40 (6)
Overall, did headache patients receive the same follow-up as usual during the pandemic? 38 (11) 62 (18) 42 (5) 58 (7) 35 (6) 65 (11)
The overall standard of care for headache patients decreased during the pandemic 54 (15) 46 (13) 36 (4) 64 (7) 65 (11) 35 (6)